W S Smith1. 1. Department of Neurology, University of California-San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA.
Abstract
BACKGROUND: The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) trial reported efficacy of the Merci Retriever for opening intracranial vessels in patients ineligible for intravenous (IV) tissue plasminogen activator (tPA). Patients who receive IV tPA but do not recanalize may also benefit from thrombectomy, but the revascularization efficacy and safety of this strategy has not been reported. METHODS: Multi MERCI is an ongoing international, multicenter, prospective, single-arm trial of patients with large vessel stroke treated within 8 hours of symptom onset. Patients were enrolled who had received IV tPA but did not recanalize or who were ineligible for IV tPA. Primary outcome was vascular recanalization (Thrombolysis in Myocardial Infarction [TIMI] score II/III) and safety. RESULTS: One hundred eleven patients received the thrombectomy procedure. Mean age +/- SD was 66.2 +/- 17.0 years, and baseline National Institutes of Health Stroke Scale (NIHSS) score was 19 +/- 6.3. Thirty patients (27%) received IV tPA before intervention. Treatment with the Retriever alone resulted in successful recanalization in 60 of 111 (54%) treatable vessels and in 77 of 111 (69%) after adjunctive therapy (IA tPA, mechanical). Symptomatic intracranial hemorrhage (ICH) occurred in 10 of 111 (9.0%). Clinically significant procedural complications occurred in 5 of 111 (4.5%) patients. The symptomatic ICH rate was 2 of 30 (6.7%) in patients pretreated with IV tPA and 8 of 81 (9.9%) in those without (P > .99). CONCLUSIONS: Mechanical thrombectomy after IV tPA seems as safe as mechanical thrombectomy alone. Mechanical thrombectomy with both first- and second-generation Merci devices is efficacious in opening intracranial vessels during acute ischemic stroke in patients who are either ineligible for IV fibrinolytic therapy or have failed IV fibrinolytic therapy.
BACKGROUND: The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) trial reported efficacy of the Merci Retriever for opening intracranial vessels in patients ineligible for intravenous (IV) tissue plasminogen activator (tPA). Patients who receive IV tPA but do not recanalize may also benefit from thrombectomy, but the revascularization efficacy and safety of this strategy has not been reported. METHODS: Multi MERCI is an ongoing international, multicenter, prospective, single-arm trial of patients with large vessel stroke treated within 8 hours of symptom onset. Patients were enrolled who had received IV tPA but did not recanalize or who were ineligible for IV tPA. Primary outcome was vascular recanalization (Thrombolysis in Myocardial Infarction [TIMI] score II/III) and safety. RESULTS: One hundred eleven patients received the thrombectomy procedure. Mean age +/- SD was 66.2 +/- 17.0 years, and baseline National Institutes of Health Stroke Scale (NIHSS) score was 19 +/- 6.3. Thirty patients (27%) received IV tPA before intervention. Treatment with the Retriever alone resulted in successful recanalization in 60 of 111 (54%) treatable vessels and in 77 of 111 (69%) after adjunctive therapy (IA tPA, mechanical). Symptomatic intracranial hemorrhage (ICH) occurred in 10 of 111 (9.0%). Clinically significant procedural complications occurred in 5 of 111 (4.5%) patients. The symptomatic ICH rate was 2 of 30 (6.7%) in patients pretreated with IV tPA and 8 of 81 (9.9%) in those without (P > .99). CONCLUSIONS: Mechanical thrombectomy after IV tPA seems as safe as mechanical thrombectomy alone. Mechanical thrombectomy with both first- and second-generation Merci devices is efficacious in opening intracranial vessels during acute ischemic stroke in patients who are either ineligible for IV fibrinolytic therapy or have failed IV fibrinolytic therapy.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse Journal: Ann Neurol Date: 1992-07 Impact factor: 10.422
Authors: Wade S Smith; Gene Sung; Sidney Starkman; Jeffrey L Saver; Chelsea S Kidwell; Y Pierre Gobin; Helmi L Lutsep; Gary M Nesbit; Thomas Grobelny; Marilyn M Rymer; Isaac E Silverman; Randall T Higashida; Ronald F Budzik; Michael P Marks Journal: Stroke Date: 2005-06-16 Impact factor: 7.914
Authors: D O Williams; J Borer; E Braunwald; J H Chesebro; L S Cohen; J Dalen; H T Dodge; C K Francis; G Knatterud; P Ludbrook Journal: Circulation Date: 1986-02 Impact factor: 29.690
Authors: C A Lewandowski; M Frankel; T A Tomsick; J Broderick; J Frey; W Clark; S Starkman; J Grotta; J Spilker; J Khoury; T Brott Journal: Stroke Date: 1999-12 Impact factor: 7.914
Authors: Y Pierre Gobin; Sidney Starkman; Gary R Duckwiler; Thomas Grobelny; Chelsea S Kidwell; Reza Jahan; John Pile-Spellman; Alan Segal; Fernando Vinuela; Jeffrey L Saver Journal: Stroke Date: 2004-10-28 Impact factor: 7.914
Authors: M Möhlenbruch; M Seifert; T Okulla; U Wüllner; D R Hadizadeh; M Nelles; S Greschus; K Wilhelm; H H Schild; T Klockgether; H Urbach Journal: Clin Neuroradiol Date: 2011-10-05 Impact factor: 3.649
Authors: Liangfu Zhu; David S Liebeskind; Reza Jahan; Sidney Starkman; Noriko Salamon; Gary Duckwiler; Fernando Vinuela; Satoshi Tateshima; Nestor Gonzalez; Pablo Villablanca; Latisha K Ali; Doojin Kim; Bruce Ovbiagele; Michael Froehler; Matthew Tenser; Jeffrey L Saver Journal: Stroke Date: 2012-01-26 Impact factor: 7.914
Authors: David Fussell; H Christian Schumacher; Philip M Meyers; Randall T Higashida Journal: Curr Neurol Neurosci Rep Date: 2007-01 Impact factor: 5.081
Authors: Patrick A Sugrue; Ziad A Hage; Daniel L Surdell; Mina Foroohar; John Liu; Bernard R Bendok Journal: Neurocrit Care Date: 2008-10-28 Impact factor: 3.210